Feed RXO
RX

RXO, Inc. RXO · NYSE

$28.63 -1.48% (-$0.43)

Summary

33 / 100 · Bulios Score

What speaks for it

  • Analysts expect revenue to grow by 19% this fiscal year.
  • It could repay all its net debt from 0.0 years of operating profit.

What to watch

  • The company made a loss over the last 12 months.
  • It passes only 3 of the 9 points of the Piotroski financial health test.
  • Revenue growth is slowing: 6.2% a year over the last 3 years against 11% over 5 years.

Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more

Score in detail

Price

Is it expensive?

Looks expensive

The company made a loss over the last 12 months, so there is no profit to set the price against.

Valuation in detail

Is it growing?

Slowly

Revenue (USD)

Diluted EPS (USD)

  • Analyst estimate

Revenue grew by 11% a year over 5 years. Over the last 3 years it grew by 6.2% a year. For the next fiscal year analysts expect revenue to grow by 19%.

Growth in detail

Does it make money?

Poorly

Over the last 12 months it made a loss of $105.0M.

Profitability in detail

Is it financially healthy?

Debt is a burden

Over the last 12 months it spent more cash than it brought in. Its debt is larger than its cash. The debt score is high even though free cash flow is negative.

Financial health in detail

Does it pay a dividend?

No

It pays no dividend.

Dividends in detail

What do analysts expect?

Neutral

Today's price within the analysts' price targets

The average target of $25.3 is 12% below today's price. 19% of the analysts recommend buying.

Analysts in detail

What does it earn on?

Fiscal year 2025

By product

By region

The company reports no revenue by region.

Truck Brokerage brings in 78% of revenue.

Segments in detail

We use essential cookies to run the website and optional analytics cookies to measure usage. See our Privacy Policy.